Pondicherry Journal of Nursing

Register      Login

VOLUME 14 , ISSUE 1 ( January-March, 2021 ) > List of Articles


A Miracle Drug for Tuberculosis: Bedaquiline

Citation Information : A Miracle Drug for Tuberculosis: Bedaquiline. 2021; 14 (1):23-24.

DOI: 10.5005/jp-journals-10084-12174

License: CC BY-NC 4.0

Published Online: 01-03-2021

Copyright Statement:  Copyright © 2021; The Author(s).


A new tuberculosis (TB) medication includes the active ingredient bedaquiline. Sirturo is a brand name for a drug that belongs to the diarylquinoline class of drugs. Bedaquiline is a diarylquinoline antimycobacterial drug that works by blocking an enzyme within the bacteria that cause TB. It prevents the proton pump of mycobacterial adenosine 5′-triphosphate (ATP) synthase. Bedaquiline is metabolized in hepatic form and eliminated in the feces. Bedaquiline is effective and safe in treating multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) patients. This drug treatment regimen was well supported and tended to a good result in this clinically relevant patient associated with MDR-TB.

  1. Basic TB Facts | TB | CDC. 27 Mar. 2020 https://www.cdc.gov/tb/topic/basics/default.htm.
  2. Global Tuberculosis Report https://www.who.int/teams/global-tuberculosis-programme/tb-reports.
  3. Tuberculosis. Wikipedia, https://en.wikipedia.org/w/index.php?title=Tuberculosis&oldid=1009354709.
  4. Jakeman B, Gross B, Fortune D, Babb S, Tinker D, Bachyrycz A. Evaluation of a pharmacist-performed tuberculosis testing initiative in New Mexico. J Am Pharmac Assoc 2015;55(3):307–312.
  5. Steingart KR, Flores LL, Dendukuri N, Schiller I, Laal S, Ramsay A, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med 2011;8(8):e1001062.
  6. “Sirturo (Bedaquiline Tablets): Uses, Dosage, Side Effects, Interactions, Warning.” RxList, https://www.rxlist.com/sirturo-drug.htm.020.
  7. Alberto M, Anna CC, Kelly DE, Afranio K. The first compound of a new class of potent anti-tuberculosis drugs. Chem Future Microbiol 2010;5:849–858.
  8. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007;3(6):323–324.
  9. Charan J, Reljic T, Kumar A. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: a systematic review. Indian J Pharmacol 2016;48(2):186.
  10. Van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug–drug interactions. J Antimicrob Chemother 2014;69(9):2310–2318.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.